Abstract
Several prognostic factors have been recognized in patients with multiple myeloma (MM). Among the most important are: the serum levels of β2-microglobulin, albumin, and LDH; the labeling index; and an abnormal karyotype. Patients with amyloidosis (AL) have poor prognosis; however, little is known concerning the prognostic significance of AL associated to MM. In 201 consecutive patients with de novo MM, we performed a fat-pad biopsy needle aspiration (FPBNA) that was stained with Congo red. Sixty eight (34%) patients had AL and a poorer prognosis disease: lower performance status, presence of B symptoms, higher LDH and calcium values, and worse response to chemotherapy. Cox regression model for overall survival detected three variables having independent prognostic significance: the presence of AL (RR = 3.4, P < 0.004), serum albumin levels <3.5 g/dl (RR 3.2, p < 0.005), and patients not achieving complete remission or very good partial remission (RR 2.9, p < 0.02). In 28% of patients with de novo MM, FPBNA was useful to detect incidental amyloidosis. During follow-up, 69% of these patients had symptoms of AL. Excluding 16 patients with obvious symptoms of AL at diagnosis, overall survival was worse in patients who developed later symptoms of AL. MM-associated AL represents a poorer prognosis disease even in the absence of symptoms at diagnosis, and this specific association may be considered as an independent high-risk prognostic factor. The routine study of periumbilical fat-pad tissue should be mandatory in all patients with MM.
Similar content being viewed by others
References
Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA et al (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 101:3801–3808 doi:10.1182/blood-2002-09-2707
Bahlis NJ, Lazarus HM (2006) Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant 38:7–15 doi:10.1038/sj.bmt.1705395
Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D et al (1997) Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 27:315–319
Fielder K, Durie BGM (1986) Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy. Am J Med 80(3):413–418 doi:10.1016/0002-9343(86)90715-1
Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70:246–256 doi:10.1097/00005792-199107000-00002
Gertz MA, Kyle RA (1994) Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 24:124–138 doi:10.1016/S0049-0172(05)80006-X
Kyle RA, Bayrd ED (1975) Amyloidosis: a review of 236 cases. Medicine 54:271–299 doi:10.1097/00005792-197507000-00001
Kyle RA (1983) Greipp, P.R. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665–683
Kyle RA (1992) Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 6:347–358
Kyle RA (1995) Prognostic factors in multiple myeloma. Stem Cells 13:56–63
Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al (1999) Long-term survival (10 years or more) in 30 patients with AL amyloidosis. Blood 93:1062–1066
Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 28(351):1860–1873 doi:10.1056/NEJMra041875
Lachmann HJ, Gallimore JR, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating immunoglobulin free light chains following chemotherapy. Br J Haematol 122:78–84 doi:10.1046/j.1365-2141.2003.04433.x
Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN (1998) The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 42:727–734
Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110(2):787–788 doi:10.1182/blood-2007-02-076034
Palladini G, Perfetti V, Merlini G (2006) Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 136:715–720
Puchtler H, Sweat F (1965) Congo red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 13(8):693–694
Rajkumar SV, Gertz MA, Kyle RA (1998) Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 104:232–237 doi:10.1016/S0002-9343(98)00037-0
San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448–455
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al (2004) High-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85–93
The UK Myeloma Forum AL Amyloidosis Guidelines Working Group (2004) Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 125:681–700 doi:10.1111/j.1365-2141.2004.04970.x
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al (1995) Poor prognosis in multiple myeloma is associated with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250–4256
Westermark P, Stenkvist B (1973) A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 132:522–523 doi:10.1001/archinte.132.4.522
Acknowledgments
We thank Dr. Sergio Giralt from M.D. Anderson Cancer Center, for his contribution in the critical review of the manuscript. The authors declare that the treatments described in the article comply with the current law of the Mexican Republic including all ethical aspects.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vela-Ojeda, J., García-Ruiz Esparza, M.A., Padilla-González, Y. et al. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. Ann Hematol 88, 59–66 (2009). https://doi.org/10.1007/s00277-008-0554-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0554-0